New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2013
08:23 EDTAMBIAmbit Biosciences FDA issues are fixable, says RW Baird
Baird remains a buyer of Ambit Biosciences as they believe the issues with the FDA are fixable. The firm expects the issues to be resolved without additional clinical work and continues to expect a 2016 launch for its AML treatment. Shares are Buy rated with a $17 price target.
News For AMBI From The Last 14 Days
Check below for free stories on AMBI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 8, 2014
07:35 EDTAMBIAmbit Biosciences begins QUANTUM-R Phase 3 clinical trial
Subscribe for More Information
April 7, 2014
07:34 EDTAMBIAmbit Biosciences announces initiation of Phase 2 cohort in quizartinib study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use